Faitot Francois, Soubrane Olivier, Wendum Dominique, Sandrini Jeremy, Afchain Pauline, Balladur Pierre, de Gramont Aimery, Scatton Olivier
Departments of Hepatobiliary Surgery and Liver Transplantation, Hôpital Saint Antoine, Paris, France.
Pathology, Hôpital Saint Antoine, Paris, France.
Surgery. 2015 Mar;157(3):444-53. doi: 10.1016/j.surg.2014.09.033. Epub 2014 Nov 6.
Bilobar colorectal metastases may be treated by a 2-stage surgical strategy. The risk of drop out after the first stage hepatectomy remains high and is associated with a nearly zero survival rate at 3 years. Our goal was to evaluate the factors predictive of the feasibility of the strategy and long-term survival, based on simple clinical and histologic features obtained from the first stage specimen.
Patients who underwent a first stage hepatectomy with curative intent were included. Preoperative clinical parameters and histologic features of the primary neoplasm and metastases obtained at the first stage hepatectomy were analyzed and compared between patients who did or did not undergo the second stage operation. A group of comparable patients treated only by chemotherapy was used as a control group.
The feasibility rate of this 2-stage resection was 76% (38/50 patients). Median survival was greater in patients treated with chemotherapy alone than for those who failed the second stage. A clinicopathologic score including male sex, segment 1 metastasis, need for >3 resection(s)/radiofrequency ablation(s), vascular invasion in the primary, need for change in type of chemotherapy, and microscopic biliary invasion by the metastasis was predictive of feasibility of the second stage and disease-free survival in patients achieving the second stage.
Combining preoperative clinical parameters with pathologic features of the primary and the metastatic lesions obtained during first stage hepatectomy predicted accurately patients who failed the second stage, and the long-term outcomes. Considering both clinical and pathologic parameters may help to define the best oncologic strategy by choosing between an exclusive chemotherapeutic or a surgical strategy.
双侧结直肠癌肝转移可采用两阶段手术策略进行治疗。一期肝切除术后的退出风险仍然很高,且与3年生存率几乎为零相关。我们的目标是基于从一期标本中获得的简单临床和组织学特征,评估预测该策略可行性和长期生存的因素。
纳入接受一期根治性肝切除术的患者。分析并比较一期肝切除术中获得的原发性肿瘤和转移灶的术前临床参数及组织学特征,比较接受或未接受二期手术的患者。一组仅接受化疗的可比患者作为对照组。
该两阶段切除术的可行性率为76%(50例患者中的38例)。单纯接受化疗的患者的中位生存期长于二期手术失败的患者。包括男性、1段转移、需要进行>3次切除/射频消融、原发性肿瘤血管侵犯、需要改变化疗类型以及转移灶镜下胆管侵犯的临床病理评分可预测二期手术的可行性以及完成二期手术患者的无病生存期。
将术前临床参数与一期肝切除术中获得的原发性和转移性病变的病理特征相结合,可准确预测二期手术失败的患者以及长期预后。综合考虑临床和病理参数可能有助于通过在单纯化疗或手术策略之间做出选择来确定最佳肿瘤治疗策略。